Russian Prime Minister Dmitry Medvedev signed a document approving the new version of the state program “The Development of Pharmaceutical and Medical Industry in 2013-2020.”
The subprogram “The Development of Drug Manufacturing” was amended by including the basic measures to create new Russian immunobiological drugs based on the world’s latest achievements in the area of immunobiology, implement the applied scientific studies and experimental R&D performed under the state contracts and R&D agreements.
The state program was extended by addition of a new section on priority development of the Russian Far East.
Due to the completion ahead of schedule in 2017 of the federal target-oriented program “The Development of Pharmaceutical and Medical Industry of the Russian Federation for the Period up to 2020 and Beyond”, the state program was extended by inclusion of some activities of the federal target-oriented program.
The list of targets and state program indicators was complemented by new indicators, such as the amount of raised extra-budgetary funds, the number of research centers established for development of world-class medicinal products and medical devices, the number of applied scientific studies and experimental R&D completed under the state contracts and R&D agreements in the area of medical industry.